2022
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2014
Tumor Lysis Syndrome: New Challenges and Recent Advances
Wilson FP, Berns JS. Tumor Lysis Syndrome: New Challenges and Recent Advances. Advances In Kidney Disease And Health 2014, 21: 18-26. PMID: 24359983, PMCID: PMC4017246, DOI: 10.1053/j.ackd.2013.07.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTumor lysis syndromeKidney failurePrevention of TLSTreatment of TLSUric acidClearance of potassiumLysis syndromeOncologic emergencyKidney manifestationsHematologic malignanciesRisk individualsMalignant cellsCancer typesPreventative effortsSecondary hypocalcemiaTreatmentHypocalcemiaHyperkalemiaHyperphosphatemiaFailureMalignancyPathophysiologyPathogenesisSyndromeEpidemiology